Coronary Flow During Rapid Heart Rates

Coronary Artery Disease Clinical Trial

— VT flow  

Official title:

Coronary Epicardial and Microcirculatory Determinants of Ventricular Tachycardia Tolerability

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05841199
• Other study ID #: 22HH7955
• Status: Recruiting
• Start date: August 1, 2023
• Est. completion date: February 2, 2026

Study information

• Verified date: November 2023
• Source: Imperial College London
• Contact: Rahul Bahl
• Phone: +44 20 7594 1093
• Email: r.bahl[@]imperial.ac.uk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this observational study is to learn about the factors which determine how well ventricular tachycardia (VT) is tolerated. The main questions it aims to answer are:

1. What impact does coronary artery disease have on the ability for a patient to tolerate VT?

2. Does treatment of coronary artery disease with stents improve the tolerability of VT?

Participants who are undergoing a clinically indicated coronary angiogram or coronary angioplasty procedure will have measurements of blood pressure, coronary pressure and coronary flow made during pacing at a range of heart rates.

Description:

Ventricular tachycardia (VT) is a common and life-threatening arrhythmia that occurs in people with heart problems. Some patients who develop this arrhythmia remain very stable with very little symptoms while others become unstable with low blood pressure or even sudden death. It is not known why some people tolerate the arrhythmia well and others do not.

If VT is not tolerated then current practice is to offer an implantable cardioverter defibrillator (ICD) which can deliver a shock to the heart if dangerous heart rhythms are detected. While shocks can be life-saving, they are also harmful, including causing psychological distress. ICDs also frequently deliver shocks when they are not needed.

If research could identify which factors predispose a person to be stable or unstable in VT, this would allow doctors to help them in a range of ways. One way would be to treat patients to improve the tolerance of VT, so avoiding the need for an ICD. Another would be to assess the the risk of instability and so allow a patient-centred decision on whether an ICD is needed.

In this study the investigators plan to recruit patients who are referred for a coronary angiogram. During the angiogram, the investigators will stimulate the heart at a range of fast heart rates and measure their blood pressure and flow in their coronary arteries. In patients who undergo stenting for a coronary stenosis, the investigators will also make these measurements after stenting so they can see if there is any difference. By recruiting a range of different cardiology patients, the investigators will be able to assess which factors contribute to stability during VT.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: February 2, 2026
• Est. primary completion date: February 2, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Able to give valid consent

• Referred for coronary angiography or coronary angioplasty

• Suitable for percutaneous physiological interrogation and PCI when clinically indicated

Exclusion Criteria:

• Unable to give valid consent

• Pregnant or breastfeeding women

• Unstable coronary artery disease (acute coronary syndrome)

• Severe multivessel coronary artery disease suitable for coronary artery bypass grafting

• Severe heart valve disease

• Severe (NYHA IV) heart failure

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Coronary Microvascular Disease
• Coronary Microvascular Dysfunction
• Heart Failure
• Microvascular Angina
• Myocardial Ischemia
• Tachycardia
• Tachycardia, Ventricular
• Ventricular Tachycardia

Intervention

Diagnostic Test:
• Pressure and flow measurement during simulated VT
Participants undergoing coronary angiography will have measurements of blood pressure, coronary pressure and coronary flow during simulated VT. VT will be simulated using pacing at a range of heart rates.

Locations

Country	Name	City	State
United Kingdom	Imperial College NHS Foundation Trust	London

Sponsors (1)

Lead Sponsor	Collaborator
Imperial College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in coronary flow in participants with different levels of coronary microvascular function.		At baseline and during simulated VT
Primary	Change in coronary flow in participants immediately before and after PCI		At baseline and during simulated VT, immediately before PCI and after PCI
Primary	Change in blood pressure in participants with different levels of coronary microvascular function.		At baseline and during simulated VT
Primary	Change in blood pressure in participants before and after PCI		At baseline and during simulated VT, immediately before PCI and after PCI
Secondary	Change in coronary flow in participants with different levels of left ventricular function		At baseline and during simulated VT
Secondary	Change in blood pressure in participants with different levels of left ventricular function		At baseline and during simulated VT